The MOPP study investigates psychological symptoms during perimenopause, their connection to previous hormone-related psychiatric issues, and symptom progression in response to hormonal therapy and/or SSRIs.
Background:
Research indicates that women in perimenopause are at increased risk for depression, likely due to hormonal fluctuations. However, the effects of hormonal treatment on perimenopausal psychological symptoms remain unexplored. Limited data also exist on anxiety, insomnia, ADHD, and worsening pre-existing conditions during this phase.
Study Objectives:
The primary objective is to assess the prevalence and types of psychological symptoms (depression, anxiety, stress, ADHD, and sleep disturbances) in patients at the menopause and MOP clinics at OLVG. Researchers will examine associations between symptoms and prior hormone-related mood disorders.
The secondary objective is to track symptom changes over 3, 6, and 12 months, analyzing the impact of hormone therapy, SSRIs, or their combination on psychological symptoms. Clusters of mood symptoms and their relationship with climacteric symptoms, previous hormone-related mood issues, insomnia, and ADHD will also be explored.
Study Methods:
Participants are recruited from OLVG. After informed consent, they complete validated questionnaires (IDS-SR, PSQI, ADHD, GCS, HADS) at 0, 3, 6, and 12 months. Baseline assessments include additional MDQ, PSST, and EPDS-Lifetime questionnaires. Data on medication use and psychiatric history are collected from medical records.
Data Analysis:
Descriptive statistics will summarize participant demographics. Binomial regressions will assess symptom prevalence and associations with prior psychiatric history. Exploratory factor analysis will identify symptom clusters. Linear regression models will evaluate symptom progression and treatment effectiveness over time.